Early Intervention for Psoriasis With Guselkumab Tied to Complete Response

WEDNESDAY, June 14, 2023 (HealthDay News) -- Guselkumab is consistently effective across subpopulations for the treatment of moderate-to-severe plaque psoriasis, according to a study published June 1 in the Journal of the European Academy of Dermatology & Venereology.
Knut Schäkel, M.D., from Heidelberg University Hospital in Germany, and colleagues evaluated the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis. The analysis included 880 patients with a short disease duration (SDD; no more than two years; 40.6 percent) or a long disease duration (LDD; more than two years) receiving guselkumab 100 mg at weeks 0, 4, 12, 20, and 28.
The researchers found that more patients with SDD achieved absolute Psoriasis Area and Severity Index (PASI) scores of 0 at week 28 (51.8 versus 39.4 percent among LDD patients) and were super responders with complete skin clearance from weeks 20 to 28 (43.7 versus 28.1 percent). The median time to PASI of 0 was shorter among SDD patients than LDD patients (141 versus 200 days). Disease duration and prior biologic use were not independently associated with super response status. Across all patient groups, guselkumab was associated with a rapid decrease in markers of systemic inflammation at week 4.
"The proportion of [super responders] was higher in SDD than LDD patients, indicating early treatment intervention may improve clinical outcomes," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Janssen-Cilag, which manufactures guselkumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Congelar óvulos podría ser la mejor opción para las mujeres que retrasan tener hijos, según un estudio
MIÉRCOLES, 1 de junio de 2022 (HealthDay News) -- No toda mujer está lista para...
What’s the Best Timing for COVID Shots in Pregnancy?
THURSDAY, June 30, 2022 (HealthDay News) -- Getting a COVID-19 vaccine during...
FDA Stretches Monkeypox Vaccine Supply by Authorizing Smaller Doses
WEDNESDAY, Aug. 10, 2022 (HealthDay) -- As at-risk Americans stand in long lines...
EASD: Factors Linked to Lower-Limb Amputation ID’d in Diabetes
WEDNESDAY, Aug. 23, 2023 (HealthDay News) -- For people with newly diagnosed...